Recent evidence reveals that the combination of liver disease and type 2 diabetes has a multiplicative effect on cardiovascular disease and mortality. But aggressive prevention can help.
WOSCOPS 20-year follow-up: 5 years of pravastatin gave lasting mortality and event benefit
Describes the 20-year follow-up of the West of Scotland Coronary Prevention Study: 5 years of pravastatin in middle-aged men with high cholesterol and no prior CHD produced a lasting legacy effect, with reduced all-cause, CV and coronary mortality and fewer heart failure and MI hospitalizations. No excess cancer or non-CV mortality was seen.


